Journal Logo

Most Popular Articles

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Vera Aguilera, Jesus; Paludo, Jonas; McWilliams, Robert R.; More

Melanoma Research. 30(4):364-375, August 2020.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Hodi, F. Stephen; Chapman, Paul B.; Sznol, Mario; More

Melanoma Research. 31(1):67-75, February 2021.

Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases

Holtkamp, Lodewijka H.J.; Chakera, Annette H.; Fung, Sebastian; More

Melanoma Research. 30(4):358-363, August 2020.

Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade

Anderson, Katie L.; Snyder, Kristin M.; Ito, Daisuke; More

Melanoma Research. 30(2):147-158, April 2020.

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis

Ziegler, Johanna S.; Kroeze, Stephanie; Hilbers, Marie-Luise; More

Melanoma Research. 30(6):552-561, December 2020.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models

Lobos-Gonzalez, Lorena; Aguilar-Guzmán, Lorena; Fernandez, Jaime G.; More

Melanoma Research. 24(2):108-119, April 2014.

A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes

Sarojini, Sreeja; Pecora, Andrew; Milinovikj, Natasha; More

Melanoma Research. 25(5):376-389, October 2015.

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Bao, Riyue; Surriga, Oliver; Olson, Daniel J.; More

Melanoma Research. 31(1):27-37, February 2021.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center

Stenehjem, David D.; Au, Trang H.; Ngorsuraches, Surachat; More

Melanoma Research. 29(6):626-634, December 2019.

Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases

Ismail, Rawa K.; Sikkes, Nienke O.; Wouters, Michel W.J.M.; More

Melanoma Research. 31(1):58-66, February 2021.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

Tarhini, Ahmad; Ghate, Sameer R.; Ionescu-Ittu, Raluca; More

Melanoma Research. 28(6):618-628, December 2018.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib

Vidarsdottir, Linda; Fernandes, Rita Valador; Zachariadis, Vasilios; More

Melanoma Research. 30(5):443-454, October 2020.

Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma

Boursi, Ben; Werner, Thomas J.; Gholami, Saeid; More

Melanoma Research. 29(3):318-321, June 2019.

A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma

Mattei, Jane; Ballhausen, Alexej; Bassett, Roland; More

Melanoma Research. 30(6):574-579, December 2020.

Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE

Rogiers, Aljosja; Vander Borght, Sara; Tuand, Krizia; More

Melanoma Research. 27(5):507-510, October 2017.

Show: